Provider/Grant Support
This activity is supported by an educational grant from Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC. Supported by an educational grant from Varian.
Credits Available
- Physicians — maximum of 2.0 AMA PRA Category 1 Credits™
- Physician Assistants — maximum of 2.0 AAPA Category 1 CME credits
- Nurses — 2.0 Nursing Contact Hours
All other healthcare professionals completing this course will be issued a statement of participation
Target Audience
This activity is intended for interventional oncologists, interventional radiologists, medical oncologists, radiation oncologists, pulmonologists, thoracic surgeons, palliative care, pathologists, advanced practice providers, pharmacists, nurse navigators and other healthcare professionals who are engaged in the care of patients with non-small cell lung cancer (NSCLC).
Program Overview
This course provides an overview of contemporary strategies in the diagnosis and management of non–small cell lung cancer (NSCLC) with an emphasis on multidisciplinary collaboration. It highlights the importance of presenting early-stage cases at tumor board to ensure that surgical, medical oncology, radiation oncology, pathology, pulmonology, and interventional radiology perspectives are incorporated into individualized treatment planning. Learners explore the growing role of liquid biopsy for detecting circulating tumor DNA, the application of next-generation sequencing to identify actionable mutations, and the expanding use of minimally invasive ablation techniques as lung-sparing options for selected patients. The course also reviews appropriate timelines for post-treatment imaging after neoadjuvant therapy and examines how biomarkers such as PD-L1 expression inform immunotherapy decisions. Collectively, the module underscores how integrated diagnostics, molecular testing, and procedural innovations shape modern NSCLC care.
Learning Objectives
Upon completion of this activity, participants should be better able to:
- Identify the key members essential for a comprehensive NSCLC Tumor Board and their roles in patient management.
- Explore essential medical treatments for NSCLC from an interventional oncologist’s and surgeon’s perspective.
- Discuss current and emerging treatment options and innovations for advanced and unresectable NSCLC, highlighting therapeutic advancements and future directions.
- Identify knowledge gaps in patient education regarding NSCLC treatment options and develop strategies to address these gaps for improved patient engagement and informed decision-making.
Faculty
Dr. Scott Atay
Thoracic Surgeon
Associate Professor of Clinical Surgery
Keck School of Medicine of the University of Southern California
Dr. Scott Genshaft
Interventional Radiologist
Director of Community Outpatient Interventional Radiology
UCLA Health
Dr. Venkatesh Krishnasamy
Interventional Radiologist
Associate Professor
University of Alabama at Birmingham
Dr. Alan Lee
Radiation Oncologist
Clinical Assistant Professor
UCLA Health
Dr. Scott Oh
Interventional Pulmonologist
Professor of Medicine
Keck School of Medicine of the University of Southern California
Dr. Karen Reckamp
Professor in Medicine
Director of the Division of Medical Oncology
Cedars-Sinai Medical Center, Los Angeles
Dr. Robert Suh
Chest Radiologist, Interventional Radiologist
Professor of Clinical Radiological Sciences
UCLA Health
Joint Accreditation Statement
In support of improving patient care, this activity has been planned and implemented by the Postgraduate Institute for Medicine and BackTable. Postgraduate Institute for Medicine is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
Credit Designation
Physician Continuing Medical Education
The Postgraduate Institute for Medicine designates this enduring material for a maximum of 2.0 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Continuing Physician Assistant Education
Postgraduate Institute for Medicine has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. This activity is designated for 2.0 AAPA Category 1 CME credits. Approval is valid until January 2, 2027. PAs should only claim credit commensurate with the extent of their participation.
Continuing Nursing Education
The maximum number of hours awarded for this Continuing Nursing Education activity is 2.0 contact hours.
Interprofessional Continuing Education
This activity was planned by and for the healthcare team, and learners will receive 2.0 Interprofessional Continuing Education (IPCE) credit for learning and change.
Disclosures of Financial Relationships
Postgraduate Institute for Medicine (PIM) requires faculty, planners, and others in control of educational content to disclose all their financial relationships with ineligible companies. All identified financial relationships are thoroughly vetted and mitigated according to PIM policy. PIM is committed to providing its learners with high quality accredited continuing education activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of an ineligible company.
The faculty reported the following relevant financial relationships with ineligible entities related to the educational content of this CE activity:
Dr. Scott Atay has no financial disclosures.
Dr. Scott Genshaft
- Consultant/Advisory Board: Boston Scientific, GE Healthcare, Intuitive Surgical, Stryker, Varian Medical
Dr. Venkatesh Krishnasamy
- Consultant/Advisory Board: Varian Medical, Instylla, Delcath, Cook, Merit, Boston Scientific
Dr. Alan Lee
- Non-Mutual Funds Stock Ownership: Telix Pharmaceuticals
Dr. Scott Oh
- Employee: Intuitive Surgical
Dr. Karen Reckamp has no financial disclosures.
Dr. Rob Suh
- Speaker (Non-CME): Neuwave Medical; Galvanize Therapeutics
- Consultant/Advisory Board: Boston Scientific, Varian Medical
The PIM planners and others have nothing to disclose. The BackTable planners and others have nothing to disclose.
All relevant financial relationships have been mitigated.
Instructions for Participation and Credit
There are no fees for participating and receiving CME credit for this enduring activity. To receive CME credit participants must:
- Read the CME/CE information and faculty disclosures.
- Participate in the online activity.
- Submit the evaluation form.
Certificates will be immediately available to the participant.
Disclosure of Unlabeled Use
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications. The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
Disclaimer
Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient's conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer's product information, and comparison with recommendations of other authorities.
Contact Information
For CME questions please contact: grants@pimed.com